Former Global Head of Oncology Translational Medicine at Novartis in China to Guide Transformation of EpimAb into Clinical Stage Oncology Company
Shanghai, China, February 27, 2018 – EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer. Dr. Peng, former Global Head of Oncology Translational Medicine Shanghai CNIBR at Novartis, was a major contributor to the worldwide clinical development of Gleevec® from Phase I to the market. He brings 25 years of international clinical development experience to EpimAb.
“We are excited to have recruited Dr. Peng to our management team as we move our first candidate EMB01, a bispecific antibody with unique properties, into the clinic,” stated Chengbin Wu, PhD, Founder and CEO of EpimAb. “Dr. Peng’s successful global leadership and expertise will be extremely beneficial to EpimAb’s portfolio of preclinical candidates, which have been developed within just two years using our proprietary bispecific antibody platform FIT-Ig®. We are proud to have him on our team and look forward to his expertise and guidance as we move forward into the next stage of EpimAb’s development.”
Discussing the appointment, Bin Peng, MD, PhD, stated, “I am delighted to join EpimAb at this transformative stage of its development. The company’s antibody platform technology is providing many new pipeline opportunities and I look forward to contributing to its future growth and continued success.”
Before joining EpimAb, Bin Peng, MD, PhD, was the Global Head of Oncology Translational Medicine, China at Novartis. Prior to this, he was appointed as the Senior Director of Clinical Pharmacology at GlaxoSmithKline, U.S. Dr. Peng served as a Senior Clinical Pharmacologist at Novartis in Switzerland where he was involved in the entire clinical development of Gleevec® from 1998 with the Phase I study in humans till its worldwide registration in 2001. Dr. Peng received his MD degree from Sun Yet-Sen University of Medical Sciences in Guangzhou, China. He then earned a PhD in Cancer Clinical Pharmacology at the Cancer Research Unit, University of Newcastle Upon Tyne, U.K and completed a postdoctoral fellowship at Manchester University, U.K. He is also an adjunct professor at Institute of Clinical Research of Beijing University and has authored more than 70 papers and abstracts on clinical pharmacology and clinical research for early cancer/hematology drugs.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com
Dr. Stephan Lensky, COO/CBO
Direct: +49 152 2610 7621
MacDougall Biomedical Communications
Direct: +49 175 5711562
Main: +49 89 2424 3494